Sep 13, 2021 / 02:15PM GMT
James Patrick Quigley - Morgan Stanley, Research Division - Equity Analyst
Great. Welcome, everybody, to this session. And I'm James Quigley, European Pharma and Biotech analyst at Morgan Stanley. It's my pleasure to welcome you to this session with MorphoSys. Today, we're joined by the CEO, Jean-Paul Kress. And just before handing over to Jean-Paul for some brief introductory comments, I'll remind you if you wish to ask a question, you can do so my entering into the text box in the portal or you can e-mail me at [email protected], and I'll ask your question for you.
Also some disclosures, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative. So with that, over to you Jean-Paul for a brief introduction.
Jean-Paul Kress - MorphoSys AG - Chairman of Management Board, MD & CEO
MorphoSys AG at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
